The RFID technology developer, backed by investors such as UPS and Intel, has filed for a $60m IPO after previously withdrawing a $100m offering in 2012.

Santen-backed Clearside Biomedical, which had raised some $48m in funding, is offering 7.2 million shares on Nasdaq priced at $7 each.

The personalised healthcare subsidiary of NantWorks, backed by Celgene, Blackberry and Allscripts, has priced its initial public offering at $14 a share.

The Naver-owned messaging platform, which first hoped to float in 2014 but dropped the plans in mid-215, is now aiming for a valuation of up to $3bn.

The biopharmaceutical company, which has raised about $480m in equity funding from backers including Novo and AbbVie, has floated on Nasdaq.

The Salesforce and Amazon-backed cloud communications company has filed for a $100m initial public offering, having been valued at $1.1bn as of July last year.

The Sanofi-backed immunotherapy company has raised $117m since it was founded in 2007, and plans to use he proceeds to advance its lead drug into phase 2 trials.

The immuno-oncology drug developer, backed by several pharmaceutical firms, has raised $55m in an IPO that saw it float substantially below its $14 to $16 range.

The sports marketing platform is planning to float in China, providing an exit to shareholders including sporting apparel producer Guirenniao.

The biosimilar developer, backed by Strides Arcolab, floated at around half the price of its range having first filed for a $115m initial public offering in January 2016.